{"id":55520,"date":"2026-01-26T21:07:34","date_gmt":"2026-01-26T13:07:34","guid":{"rendered":"https:\/\/flcube.com\/?p=55520"},"modified":"2026-01-26T21:07:36","modified_gmt":"2026-01-26T13:07:36","slug":"geneditbio-partners-with-ubrigene-on-lnp-ex-vivo-tech-for-cell-therapy-manufacturing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55520","title":{"rendered":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing"},"content":{"rendered":"\n<p><strong>GenEditBio<\/strong> announced a joint development agreement with <strong>uBriGene Biosciences International Co.<\/strong> to advance <strong>next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology<\/strong> for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce <strong>scalable, GMP\u2011grade RNA\u2011LNP reagents<\/strong> for the global cell therapy market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>GenEditBio (China) and uBriGene Biosciences International Co.<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Joint development and licensing<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Next\u2011generation LNP ex vivo delivery system<\/td><\/tr><tr><td><strong>License Scope<\/strong><\/td><td>GenEditBio grants uBriGene license for LNP technology in <strong>ex vivo applications<\/strong><\/td><\/tr><tr><td><strong>Joint Development<\/strong><\/td><td>Efficient, low\u2011toxicity RNA\u2011LNP ex vivo delivery standardized ready\u2011to\u2011use reagents<\/td><\/tr><tr><td><strong>Commercialization<\/strong><\/td><td>uBriGene to industrialize via global CRDMO platform into <strong>GMP\u2011grade raw materials<\/strong><\/td><\/tr><tr><td><strong>Target Market<\/strong><\/td><td>Global cell therapy companies (research, development, manufacturing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-strategic-rationale\">Technology Profile &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LNP Innovation:<\/strong> GenEditBio\u2019s <strong>cutting\u2011edge LNP delivery system<\/strong> enables <strong>efficient, low\u2011toxicity<\/strong> RNA transfection into cells outside the body (ex vivo), critical for <strong>CAR\u2011T, CAR\u2011NK, and stem cell therapies<\/strong><\/li>\n\n\n\n<li><strong>CRDMO Integration:<\/strong> uBriGene\u2019s <strong>ATMP\u2011focused contract development and manufacturing<\/strong> platform provides <strong>global production infrastructure<\/strong> to transform research\u2011grade reagents into <strong>scalable, GMP\u2011compliant raw materials<\/strong><\/li>\n\n\n\n<li><strong>Standardization:<\/strong> Partnership aims to create <strong>ready\u2011to\u2011use, off\u2011the\u2011shelf RNA\u2011LNP reagents<\/strong>, reducing manufacturing variability and accelerating cell therapy development timelines<\/li>\n\n\n\n<li><strong>Industrial Impact:<\/strong> Addresses <strong>bottleneck in ex vivo genetic modification<\/strong>, where current LNP formulations lack <strong>consistency and regulatory compliance<\/strong> for commercial\u2011scale cell therapy production<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Cell Therapy Market<\/strong><\/td><td>$18\u202fbillion<\/td><td>$24\u202fbillion<\/td><td>$32\u202fbillion<\/td><\/tr><tr><td><strong>Ex Vivo Gene Modification Segment<\/strong><\/td><td>$4.2\u202fbillion<\/td><td>$6.1\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>LNP Reagent Market (ATMP)<\/strong><\/td><td>$280\u202fmillion<\/td><td>$450\u202fmillion<\/td><td>$720\u202fmillion<\/td><\/tr><tr><td><strong>China ATMP CRDMO Market<\/strong><\/td><td>\u00a512\u202fbillion<\/td><td>\u00a518\u202fbillion<\/td><td>\u00a528\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Merck KGaA<\/strong> \u2013 Lipid reagents for transfection (research\u2011grade, limited GMP)<\/li>\n\n\n\n<li><strong>Thermo Fisher<\/strong> \u2013 Lipofectamine platform (not LNP\u2011based)<\/li>\n\n\n\n<li><strong>Precision NanoSystems<\/strong> \u2013 LNP manufacturing equipment and reagents<\/li>\n\n\n\n<li><strong>GenEditBio + uBriGene<\/strong> \u2013 <strong>First integrated solution<\/strong> combining <strong>proprietary LNP tech<\/strong> with <strong>end\u2011to\u2011end GMP manufacturing<\/strong> for ex vivo cell therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Scale:<\/strong> uBriGene\u2019s <strong>Suzhou GMP facility<\/strong> (capacity 10,000\u202fsqm) will host <strong>LNP reagent production lines<\/strong> by Q4\u202f2026, targeting <strong>50,000 LNP batches\/year<\/strong><\/li>\n\n\n\n<li><strong>Global Reach:<\/strong> Partnership positions both companies to supply <strong>US and EU cell therapy developers<\/strong> seeking <strong>Asian\u2011manufactured, cost\u2011competitive GMP materials<\/strong><\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> <strong>Licensing fees + per\u2011batch manufacturing margins<\/strong>; estimated <strong>$15\u201125\u202fmillion annual revenue<\/strong> by 2028 from reagent sales<\/li>\n\n\n\n<li><strong>Next Milestone:<\/strong> <strong>First GMP\u2011batch release<\/strong> of joint RNA\u2011LNP reagents expected <strong>Q3\u202f2026<\/strong>, with <strong>regulatory filings<\/strong> in US (FDA DMF) and EU (EDQM)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding technology development timelines, GMP certification, and commercial projections for LNP ex vivo reagents. Actual results may differ due to regulatory hurdles, manufacturing scale\u2011up challenges, and competitive dynamics in the ATMP supply chain.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,4525,1285],"class_list":["post-55520","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-geneditbio","tag-ubrigene-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55520\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing\" \/>\n<meta property=\"og:description\" content=\"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55520\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:07:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:07:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing\",\"datePublished\":\"2026-01-26T13:07:34+00:00\",\"dateModified\":\"2026-01-26T13:07:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"GenEditBio\",\"uBriGene Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55520#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55520\",\"name\":\"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T13:07:34+00:00\",\"dateModified\":\"2026-01-26T13:07:36+00:00\",\"description\":\"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55520\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55520#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing - Insight, China&#039;s Pharmaceutical Industry","description":"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55520","og_locale":"en_US","og_type":"article","og_title":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing","og_description":"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.","og_url":"https:\/\/flcube.com\/?p=55520","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:07:34+00:00","article_modified_time":"2026-01-26T13:07:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55520#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55520"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing","datePublished":"2026-01-26T13:07:34+00:00","dateModified":"2026-01-26T13:07:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55520"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","GenEditBio","uBriGene Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55520#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55520","url":"https:\/\/flcube.com\/?p=55520","name":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T13:07:34+00:00","dateModified":"2026-01-26T13:07:36+00:00","description":"GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next\u2011generation lipid nanoparticle (LNP) ex vivo delivery technology for advanced therapy medicinal products (ATMPs), combining GenEditBio\u2019s LNP platform with uBriGene\u2019s CRDMO capabilities to produce scalable, GMP\u2011grade RNA\u2011LNP reagents for the global cell therapy market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55520#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55520"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55520#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55520"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55520\/revisions"}],"predecessor-version":[{"id":55522,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55520\/revisions\/55522"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}